RNA
Avidity Biosciences·NASDAQ
--
--(--)
--
--(--)
4.92 / 10
Netural
Liquidity flow evaluation: 7.26/10 demonstrating robust fund flow characteristics. Optimistic Small, Medium, and Large patterns are mitigated by pessimistic overall, block, and Extra-large indicators, pointing to positive flow perspective. Research analyst consensus shows divided analyst consensus, demonstrating neutral perspective. Current ratings: Neutral(100.0%) across 10 coverage providers, supported by 2.59 historical weighted rating.
Fund Flow Rating
Analyst RatingStrong Buy
Wall Street Opinions
Strong Buy
Strong Buy
0%
Buy
0%
Hold
0%
Sell
0%
Strong Sell
0%
Date2025-10-27
InstitutionHC Wainwright & Co.
Times predicted2
Historical Win Rate50.0%
What is the analyst consensus for RNA?
- RNA holds a Bearish analyst rating, with 0% of experts assigning a Hold grade. Factoring in net Outflows from order flow data, the comprehensive Sentiment Score stands at 4.92/10 (Netural).
